Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Bigflam is a fixed-dose combination tablet containing diclofenac potassium (a nonsteroidal anti-inflammatory drug), paracetamol (an analgesic and antipyretic), and serratiopeptidase (a proteolytic enzyme). It is primarily used for the short-term relief of moderate to severe pain, inflammation, and swelling associated with musculoskeletal disorders, joint pain, arthritis (such as osteoarthritis, rheumatoid arthritis, and ankylosing spondylitis), dental pain, and post-operative recovery. Diclofenac potassium and paracetamol work synergistically to inhibit prostaglandin synthesis, thereby reducing pain and fever, while serratiopeptidase breaks down abnormal proteins at the site of inflammation to reduce swelling and promote tissue healing.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on diclofenac potassium + paracetamol + serratiopeptidase (Ultrachem Pharmaceuticals).